Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Google Secures Pentagon AI Deal for Classified Projects 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
PARSIPPANY, N.J., Feb. 11, 2016 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s fourth quarter and year ended December 31, 2015 will be released before the market opens on Thursday, February 25, 2016. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, February 25, 2016, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) ten minutes prior to the start of the call and providing the Conference ID 93538831.
A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and providing the Conference ID 93538831. The replay of the call will be available for two weeks from the date of the live call.
The live, listen-only webcast of the conference call can also be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the call.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Investor Contact: Pacira Pharmaceuticals, Inc. Jessica Cho, (973) 254-3574 [email protected]
